Please assess the completion status of the following clinical trial:

Trial Title: Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older (19 years of age or older in Canada)~2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension(OHT) in both eyes~3. Unmedicated intraocular pressure \>20mmHg and \<36mmHg in both eyes at 2 qualification visits~4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better~5. Able to give informed consent and follow study instructions~Exclusion Criteria:~Ophthalmic:~1. Clinically significant ocular disease~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles~3. Unmedicated intraocular pressure ≥36mmHg in either eye or use of more than 2 ocular hypotensive medications within 30 days of screening~4. Known hypersensitivity to any component of the formulation or latanoprost~5. Previous glaucoma surgery or refractive surgery~6. Ocular trauma within 6 months prior to screening~7. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening~8. Recent or current ocular infection or inflammation in either eye~9. Use of ocular medication in either eye of any kind within 30 days of screening and throughout of the study~10. Mean central corneal thickness \>620µm at screening in either eye~11. Any abnormality preventing reliable applanation tonometry of either eye~    Systemic:~12. Clinically significant abnormalities in lab tests at screening~13. Clinically significant systemic disease~14. Participation in any investigational study within 60 days prior to screening~15. Systemic medication that could have had a substantial effect on IOP within 30 days prior to screening, or anticipated to be used during the study~16. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PG324 Ophthalmic Solution 0.02%/0.005% (Type: EXPERIMENTAL): Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
- Netarsudil (AR-13324) ophthalmic solution 0.02% (Type: ACTIVE_COMPARATOR): Netarsudil 0.02% ophthalmic solution
- Latanoprost ophthalmic solution 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost 0.005 % ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).